List view / Grid view
A recent genomic surveillance study has demonstrated the value of genomics to inform vaccine design and highlight the challenge posted by shapeshifting bacteria.
Scientists have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 laboratories, which makes it more efficient to study the virus, and to identify new treatments.
In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.
A new study has highlighted two broadly neutralising antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations.
Governments outside of Africa have launched limited vaccinations to fight against the rising number of monkeypox cases.
Dr Roger Dmochowski, Professor of Urology and Associate Surgeon in Chief for Vanderbilt University Medical Center, discusses the promise of potential new regenerative for Stress Urinary Incontinence.
The UK National Institute of Health Research (NIHR) and UK Research and Innovation (UKRI) wish to fund research exploring if people from black, Asian and middle eastern backgrounds are disproportionately at risk from COVID-19.
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
For nearly two decades researchers have sought a way to target an oestrogen receptor in the hope they could improve breast cancer survival, but an article contends that the effort may never pan out.
Lyme disease – an infection contracted from the bite of an infected tick– is an important emerging disease in the UK, and is increasing in incidence in people in the UK and large parts of Europe and North America.
Pluristem Therapeutics announced the promising results of its non-human primates (NHP) pilot study for PLX-R18 as a treatment for Acute Radiation Syndrome (ARS).
The collaboration focuses on the delivery of an educational programme consisting of a suite of flexible Master’s level professional courses including short ones and a full Master’s programme.